Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 277

Sort by

Sort Order Select

Journal Articles

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

Blood (2025) 146 (21): 2608–2611.

https://doi.org/10.1182/blood.2025029391

Published: 2025

Includes: Supplemental data

Journal Articles

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Blood (2025) 146 (Supplement 1): 1646.

https://doi.org/10.1182/blood-2025-1646

Published: 2025

Journal Articles

Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies

Blood (2025) 146 (Supplement 1): 1641.

https://doi.org/10.1182/blood-2025-1641

Published: 2025

Journal Articles

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Roberta S. Azevedo, Christopher Manuel, Tapan Kadia, Maro Ohanian, Yesid Alvarado Valero, Wei Qiao, Jayastu Senapati, Elias Jabbour, Guillermo Garcia-Manero, Farhad Ravandi, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1634.

https://doi.org/10.1182/blood-2025-1634

Published: 2025

Journal Articles

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Roberta S. Azevedo, Hagop Kantarjian, Jayastu Senapati, Ian Bouligny, Alexandre Bazinet, Wei-Ying Jen, Amin Alousi, Uday Popat, Elizabeth Shpall, Naveen Pemmaraju, Nitin Jain, Eitan Kugler, Cody Belgarde, Elias Jabbour, Guillermo Garcia-Manero, Courtney DiNardo, Naval Daver, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 1630.

https://doi.org/10.1182/blood-2025-1630

Published: 2025

Journal Articles

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

Mina Abdelmalek, Farah Al Haj, Fadi Haddad, William Wierda, William D. Marrero, Naveen Pemmaraju, Danielle Hammond, Yesid Alvarado Valero, Gautam Borthakur, Farhad Ravandi, Hagop Kantarjian, Tapan Kadia

Blood (2025) 146 (Supplement 1): 2010.

https://doi.org/10.1182/blood-2025-2010

Published: 2025

Journal Articles

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Blood (2025) 146 (Supplement 1): 2075.

https://doi.org/10.1182/blood-2025-2075

Published: 2025

Journal Articles

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Francisco Rodolfo Saenz, Bouthaina Dabaja, Naval Daver, Farhad Ravandi, Susan Wu, Timothy Lin, Penny Fang, Jillian Gunther, Tapan Kadia, Gautam Borthakur, William Wierda, Elias Jabbour, Naveen Pemmaraju, Chelsea Pinnix, Hagop Kantarjian, Nitin Jain, Michael Spiotto

Blood (2025) 146 (Supplement 1): 1727.

https://doi.org/10.1182/blood-2025-1727

Published: 2025

Journal Articles

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Blood (2025) 146 (Supplement 1): 1726.

https://doi.org/10.1182/blood-2025-1726

Published: 2025

Journal Articles

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

Jayastu Senapati, Hagop Kantarjian, Tapan Kadia, Naveen Pemmaraju, Courtney DiNardo, Naval Daver, Andres Quesada, Austin Wilson, Kayla Farish, Fadi Haddad, Farhad Ravandi, Guillermo Garcia-Manero, Gautam Borthakur

Blood (2025) 146 (Supplement 1): 1724.

https://doi.org/10.1182/blood-2025-1724

Published: 2025

Journal Articles

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Blood (2025) 146 (Supplement 1): 487.

https://doi.org/10.1182/blood-2025-487

Published: 2025

Journal Articles

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Fadi Haddad, Hagop Kantarjian, Sara Dellasala, Ghayas Issa, Tapan Kadia, Jayastu Senapati, Rita Khouri, Nicholas Short, Courtney DiNardo, Nitin Jain, Hussein Abbas, Kelly Chien, Anwesha Ray, Naveen Pemmaraju, Farhad Ravandi, Guillermo Garcia-Manero, Koji Sasaki, Elias Jabbour

Blood (2025) 146 (Supplement 1): 5564.

https://doi.org/10.1182/blood-2025-5564

Published: 2025

Journal Articles

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Eitan Kugler, Jayastu Senapati, Sanam Loghavi, Farhad Ravandi, Alexandre Bazinet, Alex Bataller, Courtney DiNardo, Danielle Hammond, Kelly Chien, Wei-Ying Jen, Guillermo Montalban-Bravo, Koji Sasaki, Gautam Borthakur, Hagop Kantarjian, Guillermo Garcia-Manero, Tapan Kadia

Blood (2025) 146 (Supplement 1): 3206.

https://doi.org/10.1182/blood-2025-3206

Published: 2025

Journal Articles

Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL

Vanthana Bharathi, Elias Jabbour, Nicholas Short, Emmanuel Almanza, Naval Daver, Tapan Kadia, Cesar Nunez, Michael Roth, William Wierda, Yesid Alvarado Valero, Partow Kebriaei, Sa Wang, Guilin Tang, Nitin Jain

Blood (2025) 146 (Supplement 1): 6834.

https://doi.org/10.1182/blood-2025-6834

Published: 2025

Journal Articles

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Hannah Goulart, Elias Jabbour, Nitin Jain, Farhad Ravandi, Tapan Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Alex Bataller, Fadi Haddad, Rita Khouri, Jayastu Senapati, Rebecca Garris, Hagop Kantarjian

Blood (2025) 146 (Supplement 1): 3350.

https://doi.org/10.1182/blood-2025-3350

Published: 2025

Journal Articles

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Gabriel Aleixo, Heejin Cheon, Jiayin Zheng, Stephanie Soewito, Jimmy Lee, Neha Kalakuntla, Wei-Ying Jen, Sumasri Kotha, Alex Rupsee, Mia Djulbegovic, Jairo Matthews, Tapan Kadia, Timothy Olson, Taha Bat, Courtney DiNardo, Daria Babushok

Blood (2025) 146 (Supplement 1): 1418.

https://doi.org/10.1182/blood-2025-1418

Published: 2025

Journal Articles

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia

Jacob Herstein, Fadi Haddad, Kelly Chien, Yesid Alvarado Valero, Danielle Hammond, Naval Daver, Tapan Kadia, Farhad Ravandi, Kayleigh Marx, Courtney DiNardo

Blood (2025) 146 (Supplement 1): 6981.

https://doi.org/10.1182/blood-2025-6981

Published: 2025

Journal Articles

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Michelle Nwachukwu, Wei-Ying Jen, Jeremy Ramdial, Caitlin Rausch, Roberta Santos Azevedo, Gautam Borthakur, Courtney DiNardo, Naval Daver, Betul Oran, Richard Champlin, Elizabeth Shpall, Guillermo Garcia-Manero, Farhad Ravandi, Tapan Kadia

Blood (2025) 146 (Supplement 1): 6975.

https://doi.org/10.1182/blood-2025-6975

Published: 2025

Journal Articles

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Mahesh Swaminathan, Alexandre Bazinet, Koji Sasaki, Dan Fox, James Hill, Alex Bataller, Kelly Chien, Guillermo Montalban-Bravo, Danielle Hammond, Michelle Hildebrandt, Ian Bouligny, Wei-Ying Jen, Tapan Kadia, Koichi Takahashi, Courtney DiNardo, Elias Jabbour, Naval Daver, Guillermo Garcia-Manero

Blood (2025) 146 (Supplement 1): 4634.

https://doi.org/10.1182/blood-2025-4634

Published: 2025

Journal Articles

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Blood (2025) 146 (Supplement 1): 4613.

https://doi.org/10.1182/blood-2025-4613

Published: 2025

Update search

NARROW

Publications

Format

Subjects

Article Type

Topics

Date

Availability

FLAG-IDA plus venetoclax for children, adolescents, and young adults with newly diagnosed AML

A phase I study of the T-cell receptor-like antibody Hu8F4 in pts with advanced myeloid neoplasms

Results of the APG2575AU101 Study of lisaftoclax (APG-2575) combined with azacitidine (AZA) in patients with newly diagnosed (ND) or prior venetoclax–exposed myeloid malignancies

Fusion transcript dynamics as predictor of optimal molecular response in core-binding factor Acute Myeloid Leukemia

Cladribine, cytarabine, and venetoclax-based regimens are associated with durable remissions in patients (pts) with newly diagnosed Acute Myeloid Leukemia undergoing allogeneic stem cell transplantation

Phase II study of clia (cladribine, idarubicin, cytarabine) plus tyrosine kinase inhibitor (TKI) in patients with chronic myeloid leukemia in myeloid blast Phase

Outcomes of hypomethylating agent failure in patients with myelodysplastic syndromes

Radiotherapy of extramedullary acute myeloid leukemias overcomes resistance to checkpoint blockade that is enhanced by natural killer cell depletion

Characteristics, genomic landscape, and prognostic impact of trisomy 8 on contemporary outcomes in patients with newly diagnosed Acute Myeloid Leukemia (AML)

Therapy related core binding factor Acute Myeloid Leukemia (CBF-AML) responds favorably to fludarabine, cytarabine, GCSF (FLAG) based therapy: Exploratory Analysis from a Phase 2 trial

A randomized, multicenter trial of shorter durations of hypomethylating agents in lower-risk Myelodysplastic Syndromes

Outcomes of patients with chronic myeloid leukemia receiving second-line therapy after failure of frontline second-generation tyrosine kinase inhibitor

Clinical outcomes of frontline ATG-based immunosuppressive therapy in older patients with aplastic anemia

Outcomes of concomitant Philadelphia chromosome-positive and CRLF2-rearranged B-cell ALL

Consolidation with CAR T-cell therapy may abrogate the need for allogeneic stem cell transplant in patients with relapsed B-cell acute lymphoblastic leukemia after receiving dose-dense mini-hyper-CVD with inotuzumab ozogamicin and blinatumomab

Development and validation of the predictive aplastic score system (PASS): A simplified tool to diagnose acquired aplastic anemia in adults

Rhabdomyolysis in patients taking isocitrate dehydrogenase inhibitors for R/R Acute Myeloid Leukemia

Oral azacitidine as maintenance therapy post allogeneic stem cell transplant in patients with myeloid malignancies

Area deprivation index independently predicts outcomes in IPSS-R higher-risk myelodysplastic syndromes at a major cancer center

Overcoming barriers to clinical trial enrollment among adolescents and young adults with acute myeloid leukemia: Insights from a large academic cancer center

Email alerts

ASH Publications

American Society of Hematology

Update search

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only